203 related articles for article (PubMed ID: 8502815)
1. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
2. Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
Falkson G; Gelman RS; Glick J; Falkson CI; Harris J
Ann Oncol; 1992 Nov; 3(9):768-70. PubMed ID: 1450067
[No Abstract] [Full Text] [Related]
3. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
Tormey DC; Taylor SG; Gray R; Olson JE
Recent Results Cancer Res; 1984; 96():110-6. PubMed ID: 6396764
[No Abstract] [Full Text] [Related]
5. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Rossi A; Brambilla C; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772
[No Abstract] [Full Text] [Related]
7. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
[TBL] [Abstract][Full Text] [Related]
8. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant systemic therapy for resectable breast cancer.
Bonadonna G; Valagussa P
J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
[No Abstract] [Full Text] [Related]
10. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
11. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Gelber RD
Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
13. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
